Biotech Consortium India Limited (BCIL)

A. About BCIL and its composition: BCIL is a company promoted by the Department of Biotechnology (DBT), Ministry of Science and Technology, Government of India and is set up by All India Financial Institutions including IDBI, ICICI, IFCI, UTI and IFCI Venture Capital Funds Limited. It was incorporated as a public limited company in 1990 with government in advisory role and development banks as major funding agencies, with the mandate of facilitating commercialization of biotechnologies. BCIL has extensive experience in managing projects of various Government Departments and State Governments. Over the last 29 years, BCIL has assisted hundreds of clients including ministries/departments of central government, various state governments, national and international organizations, research institutions, universities, corporate sector, banks, financial institutions, first generation entrepreneurs, scientists and technologists in managing various projects/activities.

B. Services rendered in Healthcare domain: In the healthcare domain, BCIL renders services in Technology transfer, Intellectual Property (IP) management, Project management and Clinical Development Support Services. By virtue of its structure and experience in implementing various projects, BCIL has strong linkages with stakeholders in life-sciences sector including central and state government, industry, academia, entrepreneurs, international organizations etc.

i. A credible organization promoted by DBT and All India Financial Institutions with more than 29 years of experience in technology transfer and facilitating commercialization.
ii. Qualified professionals (PhDs and postgraduates) in different disciplines of life sciences.
iii. Extensive experience and expertise in transfer of technologies. Transferred more than 60 biotechnologies developed in more than 25 institutions through support from DBT, ICMR as well as CSIR.
iv. Procedures in Place for maintaining confidentiality
v. Acting as Technology-Transfer office for providing end to end solutions for IP management and technology-transfer services to the following key institutes/organisations including:
- Indian Institute of Technology (IIT), Kanpur
- Indian Institute of Technology (IIT), Roorkee
- Indian Council of Medical Research (ICMR)
- All India Institute of Medical Sciences (AIIMS)
- Translational Health Science and Technology Institute (THSTI),
- Regional Centre for Biotechnology
- etc.

vi. IP Management and Technology Transfer organization for inventions developed under the ‘School of International Biodesign’ (SIB), a flagship program of DBT, Ministry of Science and Technology, Government of India.

BCIL has several biotechnologies available for licensing. Key healthcare solutions are listed below.

i. In-vitro Diagnostic Kit: Novel Recombinant Protein based Diagnostic Kit for Hep E
Swine Hepatitis E virus diagnostic kit
USP- Detects both genotype 1& 4, Cost effective, it is safe for experimental and clinical handling.
Stage of Development- The kit has been compared with 6 diagnostic kits
ii. Medical Device:
a. A Novel, Zero Shrinkage Dental Composite
A polymeric biomaterial for restorative dentistry used in cementation of dental implants, endodontic sealers, root repair mate-rials, root end filling materials, and luting cements.
USP- Zero shrinkage, 50% reduced Enthalpy, Self-adhesive ability, Low cytotoxicity
b. Device to enable access of Computers to Physically Disabled
An assistive device for those unable to use their hands to access computers
USP- Operated by head movement and eye blink, cost effective, Wireless, Ease of use, Efficient in typing on computer by the command of eyeblink and head movement
iii. Vaccines:
a. Human Vaccine: Vaccine candidate effective against both Typhoid and Paratyphoid fever.
Combination vaccine Typhi and Paratyphi for typhoid fever.
USP- Easy purification, Effective against both S. typhi & S. paratyphi A
b. Animal Vaccine: Brucella Vaccine
Single shot, calf-hood vaccination for imparting life-long protection from Brucellosis
USP- Higher levels of IFN-γ, IgG2a, DIVA vaccine, 10-fold reduced dose, Negligible level of anti- LPS antibody

iv. Therapeutics: Novel Anti-inflammatory Biological
Recombinant protein-based Mast cells inhibitor.
USP: Non-steroidal, Mast cell inhibitor, Single injectable, Scare less recovery.

BCIL looks forward to licensing and collaboration opportunities for medical device, diagnostic technologies and other healthcare products to catalyse expedited translation of need based technologies for access to affordable and quality healthcare technologies.